Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
The drug will be available in 600 hospitals and 105 DTPs
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
